Quetmolimab Reference: HY-P99404 Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion.
Pegacaristim Reference: HY-P99815 Pegacaristim is a monoclonal antibody with thrombopoietic activity. Pegacaristim can promote generation of platelets.
Mezagitamab Reference: HY-P99730 Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
Cosibelimab Reference: HY-P99833 Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1+ cell lines, including lymphoma cells.
Tanezumab Reference: HY-P99221 Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia.
Tesnatilimab Reference: HY-P99389 Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD).
Ropeginterferon alfa-2b Reference: HY-P99348 Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms.
Sotigalimab Reference: HY-P99049 Sotigalimab, a CD40 agonistic monoclonal antibody, can be used for the research of metastatic pancreatic adenocarcinoma.
Dalotuzumab Reference: HY-P99284 Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo.
Cinpanemab Reference: HY-P99356 Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.
Tamgiblimab Reference: HY-P99508 Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects.
Apolizumab Reference: HY-P99442 Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro.